- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Docetaxel and GM-CSF
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 4
- States / cities
- San Francisco, California • Boston, Massachusetts • Portland, Oregon + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 8,949
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Advanced Solid Tumor
- Interventions
- ARV-6723, Pembrolizumab, SOC
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 3
- States / cities
- Huntersville, North Carolina • San Antonio, Texas • Fairfax, Virginia
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 14
- States / cities
- Iowa City, Iowa • Kansas City, Kansas • New Orleans, Louisiana + 11 more
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
- Interventions
- ONM-501, Cemiplimab
- Drug
- Lead sponsor
- OncoNano Medicine, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
- Conditions
- Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
- Interventions
- Cabozantinib, Sunitinib Malate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 3
- States / cities
- Houston, Texas • Sugar Land, Texas
- Conditions
- Prostate Adenocarcinoma, Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Angiogram, Catheterization, Gallium Ga-labeled PSMA-11, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Ryan Kohlbrenner, MD
- Other
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Kidney Cancer
- Interventions
- therapeutic allogeneic lymphocytes
- Biological
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 138
- States / cities
- Birmingham, Alabama • Athens, Georgia • Augusta, Georgia + 107 more
- Conditions
- Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma, Breast Carcinoma, Ovarian Carcinoma, Exocrine Pancreatic Carcinoma, Gastric Carcinoma, Melanoma
- Interventions
- SGN-CD47M
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 5
- States / cities
- Cleveland, Ohio • Portland, Oregon • Nashville, Tennessee + 2 more
- Conditions
- Bladder Cancer
- Interventions
- Specimen and questionnaires only
- Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 60 Years and older · Male only
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 2
- States / cities
- Rochester, New York • Houston, Texas
- Conditions
- Uterine Cancer
- Interventions
- Ifosfamide, Radiation Therapy, Cisplatin
- Drug · Device
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Prostate Cancer
- Interventions
- Ceevra Reveal
- Device
- Lead sponsor
- Ceevra, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Prostate Cancer
- Interventions
- Behavioral Exercise Training (BET) intervention
- Behavioral
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 41 Years to 85 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Depression, Fatigue, Ovarian Cancer
- Interventions
- Home yoga practice, yoga classes
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Kidney Neoplasms
- Interventions
- Thalidomide, Capecitabine
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation, ATM Gene Mutation, MMR Mutation, Lynch Syndrome, Genetic Predisposition to Disease
- Interventions
- Prostate cancer screening
- Diagnostic Test
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 35 Years to 74 Years · Male only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2040
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Prostate Cancer, Prostate Cancer
- Interventions
- 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, FTT-PET/CT, EnhanceAR-Seq
- Drug · Device · Diagnostic Test
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Sipuleucel-T, APC-Placebo
- Biological
- Lead sponsor
- Dendreon
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 65
- States / cities
- Laguna Hills, California • Loma Linda, California • Los Angeles, California + 49 more
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- ZEN003694
- Drug
- Lead sponsor
- Zenith Epigenetics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Francisco, California • Detroit, Michigan + 5 more
- Conditions
- Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Interventions
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Epacadostat, Laboratory Biomarker Analysis, Pharmacological Study, Poly ICLC
- Biological · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Balstilimab, Biospecimen Collection, Botensilimab, Computed Tomography, Nephrectomy, Questionnaire Administration
- Biological · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
- Interventions
- filgrastim, docetaxel, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Prostate Cancer
- Interventions
- Cabozantinib, Abiraterone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
- Interventions
- Exemestane, Laboratory Biomarker Analysis, Pharmacokinetic Study, Questionnaire Administration
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Minneapolis, Minnesota • Madison, Wisconsin